Cancer Biomark. 2017 Dec 12;21(1):221-228. doi: 10.3233/CBM-170670.
Non-small cell lung cancer (NSCLC) is the main type of lung cancer. While miR-186 is significantly reduced in lung cancer tissues and cells, its role in NSCLC has not been completely elucidated.
We used qRT-PCR and western blot methods to investigate the levels of miR-186 and YY1 in 21 pairs of NSCLC tissues. Dual luciferase reporter gene assays were performed to detect whether miR-186 directly targets YY1. Next, the roles of miR-186 and its target gene (YY1) in determining the proliferation, apoptosis and migration capabilities of selected cell lines (A549 and HCC827) were investigated by using miR-186 mimics or YY1 siRNA.
Our results showed that miR-186 was downregulated and YYI was upregulated in NSCLC tissue, and miR-186 expression was negatively associated with YY1. Similarly, miR-186 was also downregulated and YY1 expression also was upregulated in both A549 and HCC827 cells; furthermore, miR-186 was found to directly target YY1. Cell proliferation, invasion, and migration, as well as apoptosis induction were more strongly inhibited by YY1 siRNA than by miR-186.
Our results suggest that miR-186 and its target gene (YY1) could possibly serve as new prognostic biomarkers and therapeutic targets for treating NSCLC in humans.
非小细胞肺癌（NSCLC）是肺癌的主要类型。miR-186 在肺癌组织和细胞中显著降低，但其在 NSCLC 中的作用尚未完全阐明。
我们使用 qRT-PCR 和 Western blot 方法检测了 21 对 NSCLC 组织中 miR-186 和 YY1 的水平。双荧光素酶报告基因实验检测 miR-186 是否直接靶向 YY1。接下来，通过使用 miR-186 模拟物或 YY1 siRNA，研究 miR-186 和其靶基因（YY1）在决定选定细胞系（A549 和 HCC827）的增殖、凋亡和迁移能力方面的作用。
我们的结果表明，miR-186 在 NSCLC 组织中下调，YY1 上调，miR-186 的表达与 YY1 呈负相关。同样，miR-186 在 A549 和 HCC827 细胞中也下调，YY1 表达上调；此外，miR-186 被发现可以直接靶向 YY1。与 miR-186 相比，YY1 siRNA 更强烈地抑制细胞增殖、侵袭和迁移，以及诱导细胞凋亡。
我们的结果表明，miR-186 和其靶基因（YY1）可能成为人类治疗 NSCLC 的新的预后生物标志物和治疗靶点。
